{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:24Z","timestamp":1791414144000,"version":"4.3.3"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007625"],"award-info":[{"award-number":["INV-007625"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejps.2025.107160","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T10:10:40Z","timestamp":1749377440000},"page":"107160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Population pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial"],"prefix":"10.1016","volume":"212","author":[{"given":"Weijie","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-8192","authenticated-orcid":false,"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107160_bib0004","first-page":"223","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Sci. (1979)"},{"key":"10.1016\/j.ejps.2025.107160_bib0001","first-page":"14","article-title":"Chemical classes presenting novel antituberculosis agents currently in different phases of drug development: a 2010-2020 review","author":"Angula","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.ejps.2025.107160_bib0006","unstructured":"Anonymous. 2012. Clinical pharmacology biopharmaceutics review(s) (bedaquiline)."},{"key":"10.1016\/j.ejps.2025.107160_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2025.107160_bib0016","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107160_bib0017","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107160_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128824","article-title":"Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent","volume":"71","author":"Huang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2025.107160_bib0012","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107160_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/psp4.12049","article-title":"Good practices in model-informed drug discovery and development: practice, application, and documentation","volume":"5","author":"Marshall","year":"2016","journal-title":"CPT. Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107160_bib0018","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/AAC.01418-13","article-title":"Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug","volume":"58","author":"McLeay","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2025.107160_bib0013","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107160_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00463-19","article-title":"Daily dosing for bedaquiline in patients with tuberculosis","volume":"63","author":"Salinger","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2025.107160_bib0019","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/psp4.12147","article-title":"Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin","volume":"5","author":"Svensson","year":"2016","journal-title":"CPT. Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107160_bib0005","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/psp4.12722","article-title":"Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis","volume":"10","author":"Tanneau","year":"2021","journal-title":"CPT. Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107160_bib0003","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tim.2013.05.002","article-title":"Rising to the challenge: new therapies for tuberculosis","volume":"21","author":"Wong","year":"2013","journal-title":"Trends. Microbiol."},{"key":"10.1016\/j.ejps.2025.107160_bib0002","series-title":"Global Tuberculosis Report 2022","year":"2022"},{"key":"10.1016\/j.ejps.2025.107160_bib0007","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/phar.1482","article-title":"Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis","volume":"34","author":"Worley","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2025.107160_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejps.2025.107160_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13718","article-title":"Safety, pharmacokinetics, and food effect of sudapyridine (WX-081), a novel anti-tuberculosis candidate in healthy Chinese subjects","volume":"17","author":"Yu","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejps.2025.107160_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01372-22","article-title":"In vitro activity of the sudapyridine (WX-081) against non-tuberculous mycobacteria isolated in Beijing, China","volume":"10","author":"Zhu","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejps.2025.107160_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00811-22","article-title":"Population pharmacokinetic modeling of bedaquiline among multidrug-resistant pulmonary tuberculosis patients from China","volume":"66","author":"Zou","year":"2022","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T10:13:06Z","timestamp":1757844786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"alternative-id":["S0928098725001599"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107160","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107160"}}